

Dr. Henning Gädeke,
Chair of the Global Health EDCTP3 Joint Undertaking Governing Board
c/o Dr. Michael Makanga,
Global Health EDCTP3 Joint Undertaking Executive Director
Global Health EDCTP3 Joint Undertaking
56 – 60 Avenue de la Toison d’Or
1060 Brussels
Belgium

Letter of endorsement

RE: Participation in the project "Enhanced Surveillance and Treatment Adaptation for Artemisinin Resistance in Africa (E-STAR)" submitted under the HORIZON-JU-GH-EDCTP3-2025-01-MALARIA-02 call

Oxford, 28 August 2025

Dear Dr Gädeke,

On behalf of the “The Chancellor, Masters and Scholars of the University of Oxford” at the University Offices (University of Oxford, UOXF), based at Wellington Square, Oxford, OX1 2JD, United Kingdom, (VAT registration GB125506730) and in accordance with Council Regulation (EU) No 2085/2021 of 19th November 2021 establishing the joint undertakings under Horizon Europe and specifically Article 9 therein, I hereby submit an application to become a contributing partner to the Global Health EDCTP3 Joint Undertaking (Global Health EDCTP3 JU).

The Nuffield Department of Medicine (NDM, www.ndm.ox.ac.uk) at the University of Oxford is a world-leader in global health with significant contributions through research, innovation, and capacity building. Within the Department, the Centre for Tropical Medicine and Global Health brings together 14 infectious disease research units in Oxford, Africa, and Southeast Asia.

NUFFIELD DEPARTMENT of MEDICINE

University of Oxford, Henry Wellcome Building for Molecular Physiology,
Old Road Campus, Oxford, OX3 7BN, United Kingdom

Tel: +44 (0)1865 287500

www.ndm.ox.ac.uk

The Infectious Diseases Data Observatory (IDDO) in Oxford, led by Prof. Philippe Guerin, has world-leading expertise in the collection, standardisation, and meta-analysis of individual patient data (IPD) from a range of infectious diseases, in particular for malaria through the work of the WorldWide Antimalarial Resistance Network (WWARN) established in 2009. IDDO/WWARN maintains the largest repository of clinical, molecular, pharmacological, and in vitro malaria data, freely available for reuse. The project generates evidence-based guidance used by the WHO to shape antimalarial treatment policies towards better control and efficacy, and leads surveillance projects on antimalarial drug resistance, including the MARC-SE project funded by the Global Health EDCTP3 Joint Undertaking under the European Union's Horizon Europe programme to monitor and model resistance in Southern and Eastern Africa. IDDO/WWARN also developed and maintains the WWARN Clinical Trial library database to address drug resistance and provide free guidance, visualisation tools, and training to identify research gaps and enhance understanding of antimalarial drug resistance, aiding clinical trial development and research analysis.

The IDDO EQA programme, led by Dr. Mehul Dhorda, provides accreditation for laboratories performing antimalarial drug level measurements. Dr Dhorda also coordinates clinical trials on antimalarial treatments, including triple antimalarial combination therapies. Prof. Joel Tarning, an expert in pharmacometrics modelling, and his team work to optimise drug dosing to improve antimalarial treatments for vulnerable populations, especially children and pregnant women, where accurate dosing is critical to safety and efficacy.

The IDDO team is committed to supporting the implementation of the E-STAR proposal's objectives. They will provide expertise in clinical trial design, pharmacovigilance and efficacy testing, data management, statistical analyses, geospatial modelling, and establishing and maintaining the data platform, specifically leading and contributing to the Scientific Leadership of the project (WP2), Molecular Surveillance Network (WP3), Adaptive MAMS Clinical Trial (WP4), Point-Of-Care Diagnostic Validation (WP5), Data Management, Bioinformatics and Modelling (WP7), and Dissemination, Communication, Exploitation and Policy Translation (WP9). They will also provide secure data governance infrastructure, advanced analytics, and training on FAIR-compliant data sharing principles and IPD meta-analysis methodologies, ensuring the rapid integration of new findings into the global evidence base on antimalarial drug resistance.


The total value of the University of Oxford's in-kind contribution to the E-STAR project is 609,831 EUR, above the 20% threshold, including personnel time, overhead costs, and use of facilities and infrastructure at the University of Oxford across the research sites.

We confirm the following:

1. We will comply with the Horizon Europe Regulation (EU) No 2021/695; Council Regulation (EU) No 2085/2021 establishing the joint undertakings under Horizon Europe; the Model Grant Agreement for Horizon Europe and applicable Global Health EDCTP3 JU rules, including the relevant work programmes and in particular the call conditions therein.
2. We will keep all information received in the context of our involvement as a contributing partner to the Global Health EDCTP3 JU confidential. This confidentiality obligation applies in particular but is not limited to the areas of Global Health EDCTP3 JU call topic preparation and publication, proposal submission and evaluation, and consortium formation. We further understand that this obligation strictly prohibits the release of confidential information to any legal entities, save where specifically authorised by Global Health EDCTP3 JU. Internal dissemination of information within our organisation will be done on the basis of the “need-to-know” principle.
3. We are confident of our ability to fulfil the above commitments and further confirm our understanding that the Global Health EDCTP3 JU will allocate resources to the above topic based on these commitments.
4. The value of our contribution will be based on costs calculated in accordance with Article 6 of the Horizon Europe Model Grant Agreement.
5. We accept that additional modalities regarding the provision of our contribution may be defined in subsequent agreements or documents, such as a funding agreement and topic text.

E-STAR is a vital initiative that will strengthen Africa-led malaria surveillance, advancing global monitoring and modelling of resistance and establishing long-term infrastructure and research capacity at strategic sites. The University of Oxford and the NDM are fully committed to supporting this mission through the provisions and in-kind contributions listed. We look forward to collaborating with partners across countries and institutions to implement the objectives of this project successfully.

Yours faithfully,



2025.09.30 16:47:46 +
01'00'

Deputy Business Manager

Centre for Tropical Medicine and Global Health

Nuffield Department of Medicine

